Coloplast 관리

관리 기준 확인 4/4

Coloplast CEO는 Kristian Villumsen, Dec2018 에 임명되었습니다 의 임기는 5.92 년입니다. 총 연간 보상은 DKK 22.00M, 55.9% 로 구성됩니다. 55.9% 급여 및 44.1% 보너스(회사 주식 및 옵션 포함). 는 DKK 90.15M 가치에 해당하는 회사 주식의 0.045% 직접 소유합니다. 90.15M. 경영진과 이사회의 평균 재임 기간은 각각 5.9 년과 6.8 년입니다.

주요 정보

Kristian Villumsen

최고 경영자

DKK 22.0m

총 보상

CEO 급여 비율	55.9%
CEO 임기	5.9yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	5.9yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Kristian Villumsen 의 보수는 Coloplast 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	DKK 22m	DKK 12m	DKK 5b
Jun 30 2024	n/a	n/a	DKK 5b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	n/a	n/a	DKK 5b
Sep 30 2023	DKK 23m	DKK 12m	DKK 5b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b

보상 대 시장: Kristian 의 총 보상 ($USD 3.10M ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.70M ).

보상과 수익: Kristian 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Kristian Villumsen (54 yo)

5.9yrs

테뉴어

DKK 22,000,000

보상

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kristian Villumsen	President & CEO	5.9yrs	DKK 22.00m	0.045% DKK 90.1m
Anders Lonning-Skovgaard	Executive VP & CFO	10.3yrs	DKK 11.30m	0.0012% DKK 2.4m
Allan Rasmussen	Executive Vice President of Global Operations	10.3yrs	DKK 9.90m	0.011% DKK 22.7m
Nicolai Andersen	Executive Vice President of Chronic Care	no data	DKK 9.50m	데이터 없음
Paul Marcun	Executive Vice President of Growth	5.8yrs	DKK 11.50m	0.014% DKK 27.1m
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000020% DKK 40.1k
Aleksandra Dimovska	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Dennis Kaysen	Vice President of Corporate Communications	no data	데이터 없음	데이터 없음
Dorthe Ronnau	Executive Vice President of People & Culture	2.8yrs	데이터 없음	데이터 없음
Alain Morvan	Senior Vice President of Sales Europe	12.6yrs	데이터 없음	데이터 없음
Caroline Rosenstand	Executive Vice President of Voice & Respiratory Care	no data	데이터 없음	데이터 없음
Rasmus Møller	Senior Vice President of Wound & Skin Care	4.2yrs	데이터 없음	데이터 없음

5.9yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 0QBO 의 관리팀은 노련하고 경험 (평균 재직 기간 5.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Barfod	Senior Controller & Employees Representative Director	18.8yrs	DKK 450.00k	0.000020% DKK 40.1k
Carsten Hellmann	Independent Director	6.9yrs	DKK 690.00k	0.0027% DKK 5.3m
Lars Rasmussen	Independent Chairman of the Board	5.9yrs	DKK 1.84m	0.0054% DKK 10.8m
Niels Louis-Hansen	Deputy Chairman	56.8yrs	DKK 938.00k	1.93% DKK 3.9b
Marianne Wiinholt	Independent Director	3.9yrs	DKK 880.00k	0.00022% DKK 440.8k
Jette Nygaard-Andersen	Independent Director	8.9yrs	DKK 600.00k	데이터 없음
Nikolaj Gundersen	Employees Representative Director	6.8yrs	DKK 450.00k	데이터 없음
Roland Pedersen	Employees Representative Director	6.8yrs	DKK 450.00k	0.00072% DKK 1.4m
Annette Bruls	Independent Director	2.9yrs	DKK 600.00k	데이터 없음

6.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 0QBO 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

Coloplast 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Deputy Chairman recently bought kr.40m worth of stock

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings released: EPS: kr.22.46 (vs kr.22.21 in FY 2023)

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Third quarter 2024 earnings released: EPS: kr.5.67 (vs kr.5.99 in 3Q 2023)

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

First half dividend of kr.5.00 announced

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023)

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Full year 2023 earnings released

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021)

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

New 90-day low: kr.860

Revenue beats expectations

First quarter 2021 earnings released

New 90-day high: kr.1,018

New 90-day low: kr.883

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

New 90-day low: kr.924

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

New 90-day low: kr.970

New 90-day low: kr.971

New 90-day low - kr.986

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

New 90-day low - kr.1,002

Earnings released

CEO 보상 분석